Evidence map›Paper›PMID 26282601›Full record

ArticleNature communications2015

BMP signalling differentially regulates distinct haematopoietic stem cell types.

Mihaela Crisan, Parham Solaimani Kartalaei, Chris S Vink, Chris Vink, Tomoko Yamada-Inagawa, Karine Bollerot, Wilfred van IJcken, Reinier van der Linden, Susana M Chuva de Sousa Lopes, Rui Monteiro and 2 more

Erratum issuedAbstract read
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Unraveling the role ofHemaSphere · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. The evolving hematopoietic niche during development.Frontiers in molecular biosciences · 2024
    Review
  16. LinCell proliferation · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. PDGFRβCell reports · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mihaela Crisan1] Department of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands [2] University of Edinburgh, Centre for Inflammation Research, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
Parham Solaimani Kartalaei1] Department of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands [2] University of Edinburgh, Centre for Inflammation Research, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
Chris S Vink1] Department of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands [2] University of Edinburgh, Centre for Inflammation Research, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
Chris Vink1] Department of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands [2] University of Edinburgh, Centre for Inflammation Research, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
Tomoko Yamada-InagawaDepartment of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
Karine BollerotDepartment of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
Wilfred van IJckenCenter for Biomics, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, Netherlands.ORCID 0000000204218301
Reinier van der LindenDepartment of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands.
Susana M Chuva de Sousa LopesDepartment of Anatomy and Embryology, Leiden University Medical Center, Building 2, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Rui MonteiroDepartment of Anatomy and Embryology, Leiden University Medical Center, Building 2, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.ORCID 0000000242238506
Christine MummeryDepartment of Anatomy and Embryology, Leiden University Medical Center, Building 2, Einthovenweg 20, 2333 ZC Leiden, The Netherlands.
Elaine Dzierzak1] Department of Cell Biology, Erasmus MC Stem Cell Institute, Erasmus Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands [2] University of Edinburgh, Centre for Inflammation Research, Queens Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.

Funding

Characterization of the first HSCs during mouse ontogenyR37DK054077 · NIDDK · UNIVERSITY OF EDINBURGH · PI DZIERZAK, ELAINE A · 2006 to 2015
$2.7M
FIRST HSCS DURING MOUSE ONTOGENYR01DK054077 · NIDDK · ERASMUS UNIVERSITY OF ROTTERDAM · PI DZIERZAK, ELAINE A · 1998 to 2005
$854k
NIDDK NIH HHS R037 DK54077NIDDK NIH HHS R37 DK054077
6 · The paper itself

Abstract

Adult haematopoiesis is the outcome of distinct haematopoietic stem cell (HSC) subtypes with self-renewable repopulating ability, but with different haematopoietic cell lineage outputs. The molecular basis for this heterogeneity is largely unknown. BMP signalling regulates HSCs as they are first generated in the aorta-gonad-mesonephros region, but at later developmental stages, its role in HSCs is controversial. Here we show that HSCs in murine fetal liver and the bone marrow are of two types that can be prospectively isolated--BMP activated and non-BMP activated. Clonal transplantation demonstrates that they have distinct haematopoietic lineage outputs. Moreover, the two HSC types differ in intrinsic genetic programs, thus supporting a role for the BMP signalling axis in the regulation of HSC heterogeneity and lineage output. Our findings provide insight into the molecular control mechanisms that define HSC types and have important implications for reprogramming cells to HSC fate and treatments targeting distinct HSC types.

Indexed as

AnimalsBenzofuransBone Morphogenetic ProteinsEmbryo, MammalianFemaleGene Expression Regulation, DevelopmentalGreen Fluorescent ProteinsHematopoietic Stem CellsMaleMiceMice, TransgenicNerve Tissue ProteinsNuclear ProteinsQuinolinesSignal Transduction(3aS,4S,9bS)-N-(2-(8-cyano-1-formyl-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo(3,2-c)quinolin-4-yl)-2-methylpropyl)-4,6-difluorobenzofuran-2-carboxyamideBabam2 protein, mouseBenzofuransBone Morphogenetic ProteinsGreen Fluorescent ProteinsNerve Tissue ProteinsNuclear ProteinsQuinolines

Identifiers

PMID26282601
PMCPMC4557333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.